Clinical trial
Evaluating the Safety and Efficacy of PDE-5 Inhibitor: Tadalafil as a Treatment for Early Stages of Alzheimer's Disease
NCT07172815 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluating the Safety and Efficacy of PDE-5 Inhibitor: Tadalafil as a Treatment for Early Stages of Alzheimer's Disease
- Lead sponsor
- Imperial College London
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2025
- Completion date
- August 31, 2028
- Enrollment
- 244 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.